electroCore, Inc.

electroCore, Inc. (Nasdaq Capital Stock Market: ECOR) operates as a bioelectronic technology company dedicated to improving health and quality of life through innovative non-invasive bioelectronic therapies. The company's website is www.gammaCore.com.

The company generates revenues from two principal product categories: personal use prescription medical devices for managing specific medical conditions and personal use consumer products promoting general wellness and human performance. electroCore's core offerings include gammaCore, a prescription handheld medical device FDA cleared for treating various primary headache conditions including migraine, cluster headache, hemicrania continua, and paroxysmal hemicrania. The company also markets Quell Fibromyalgia, an FDA-authorized prescription wearable neuromodulation device designed to reduce fibromyalgia symptoms in adults with high pain sensitivity. Additionally, electroCore sells Truvaga handsets for general health and wellbeing through direct-to-consumer channels and online retailers, and TAC-STIM products developed in collaboration with the United States Department of Defense for human performance applications.

The United States Department of Veterans Affairs represented 71.2 percent of revenue during the fiscal year ended December 31, 2025, with sales primarily conducted through the Federal Supply Schedule contract expiring June 14, 2030. The United Kingdom National Health Service comprised 4.4 percent of revenue through the MedTech Funding Mandate program. The company maintains distribution partnerships in select territories outside the United States and United Kingdom.

electroCore employs 83 full-time employees as of February 1, 2026, and operates manufacturing and fulfillment facilities in Rockaway, New Jersey. The company holds more than 215 patents and patent applications, including 170 issued U.S. patents, and maintains a trademark portfolio consisting of 23 U.S. trademark registrations and over 40 international trademark registrations. The company's intellectual property portfolio includes proprietary nVNS technology, smartphone-integrated therapy delivery systems, and the Quell Health Cloud for data analytics and scientific research applications.